HIGHLIGHTS
- who: Christopher J. Walker from the WUGEN, United States Central South University, China have published the paper: Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms, in the Journal: (JOURNAL)
- what: In this study, the XPO1 inhibitors, selinexor and eltanexor, were investigated as anti-cancer agents in five different chordoma patient-derived xenograft (PDX) models, as single agents or in combinations with bortezomib or abemaciclib. The work demonstrated the effectiveness of the SINE compounds selinexor and eltanexor in reducing growth of PDX models . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.